LB Partners LLC Decreases Stock Holdings in Liquidia Co. (NASDAQ:LQDA)

LB Partners LLC reduced its stake in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 29.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 200,000 shares of the company's stock after selling 82,947 shares during the period. Liquidia accounts for 1.7% of LB Partners LLC's portfolio, making the stock its 14th biggest holding. LB Partners LLC owned 0.26% of Liquidia worth $2,000,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. DMC Group LLC lifted its holdings in Liquidia by 36.7% in the 3rd quarter. DMC Group LLC now owns 13,883 shares of the company's stock worth $139,000 after purchasing an additional 3,725 shares in the last quarter. Creative Planning purchased a new position in Liquidia in the 3rd quarter worth approximately $170,000. Sapient Capital LLC purchased a new position in Liquidia in the 3rd quarter worth approximately $1,336,000. SG Americas Securities LLC purchased a new position in Liquidia in the 3rd quarter worth approximately $210,000. Finally, Whitcomb & Hess Inc. lifted its holdings in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company's stock worth $116,000 after purchasing an additional 1,074 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Trading Down 0.4 %

Shares of NASDAQ LQDA traded down $0.05 during trading hours on Monday, hitting $11.09. 1,005,830 shares of the company traded hands, compared to its average volume of 1,004,009. The stock has a market capitalization of $847.43 million, a price-to-earnings ratio of -7.12 and a beta of 0.22. The company's 50 day moving average price is $10.41 and its 200 day moving average price is $11.89. Liquidia Co. has a 12 month low of $6.04 and a 12 month high of $16.99.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The business had revenue of $3.66 million for the quarter, compared to analysts' expectations of $7.92 million. Equities analysts anticipate that Liquidia Co. will post -1.69 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Oppenheimer began coverage on Liquidia in a report on Tuesday, June 25th. They issued a "market perform" rating on the stock. Lifesci Capital began coverage on Liquidia in a research note on Thursday, October 3rd. They issued an "outperform" rating and a $30.00 price objective on the stock. Needham & Company LLC reaffirmed a "buy" rating and issued a $25.00 price objective on shares of Liquidia in a research note on Monday, August 19th. Scotiabank began coverage on Liquidia in a research note on Wednesday, October 16th. They issued a "sector outperform" rating and a $30.00 price objective on the stock. Finally, BTIG Research reduced their price objective on Liquidia from $29.00 to $25.00 and set a "buy" rating on the stock in a research note on Monday, August 19th. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $24.67.

Insider Activity at Liquidia

In related news, insider Rajeev Saggar sold 2,260 shares of the business's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the transaction, the insider now owns 207,383 shares in the company, valued at $2,304,025.13. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Liquidia news, CFO Michael Kaseta sold 3,892 shares of the company's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $43,240.12. Following the completion of the sale, the chief financial officer now directly owns 311,076 shares in the company, valued at approximately $3,456,054.36. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rajeev Saggar sold 2,260 shares of the company's stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $25,108.60. Following the completion of the sale, the insider now owns 207,383 shares of the company's stock, valued at $2,304,025.13. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 20,858 shares of company stock worth $228,724 in the last quarter. 31.60% of the stock is owned by company insiders.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).